Unaudited Condensed Consolidated Statement of Cash Flows	3 Months Ended	9 Months Ended
	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Cash flows from operating activities:
Net loss	$ (18,957,000)	$ (51,878,000)	$ (65,318,000)
Adjustments to reconcile net loss to net cash used in operations:
Share-based compensation		24,948,000	25,443,000
Depreciation and amortization		5,345,000	5,247,000
Amortization of right-of-use assets		1,975,000	2,327,000
Allowance for doubtful accounts		250,000	529,000
Impairment of right-of-use assets	0	186,000	0
Loss on impairment of long lived assets		0	536,000
Change in fair value of warrant liabilities	(907,000)	(7,659,000)	2,715,000
Changes in operating assets and liabilities:
Accounts receivable		(1,139,000)	(857,000)
Prepaid expenses and other assets		(2,179,000)	1,590,000
Accounts payable		(58,000)	(1,318,000)
Accrued expenses and other liabilities		(931,000)	2,011,000
Accrued compensation and benefits		302,000	(4,472,000)
Operating lease liabilities		(1,785,000)	(3,317,000)
Other		(10,000)	0
Net cash used in operating activities		(32,633,000)	(34,884,000)
Cash flows from investing activities:
Receipts of term deposit maturities		6,559,000	0
Purchases of property and equipment		(792,000)	(113,000)
Capitalized internal-use software development costs		(48,000)	0
Purchases of term deposits		0	(3,180,000)
Net cash provided by (used in) investing activities		5,719,000	(3,293,000)
Cash flows from financing activities:
Proceeds from exercise of options		473,000	353,000
Taxes withheld and paid related to net share settlement of equity awards		(3,843,000)	(557,000)
Net cash used in financing activities		(3,370,000)	(204,000)
Effect of changes in currency exchange rates on cash and cash equivalents		57,000	(158,000)
Net decrease in cash and cash equivalents		(30,227,000)	(38,539,000)
Cash, cash equivalents and restricted cash, beginning of the period		145,784,000	194,965,000
Cash, cash equivalents and restricted cash, end of the period	156,426,000	115,557,000	156,426,000
Reconciliation of cash, cash equivalents and restricted cash to the amounts reported within the consolidated balance sheets
Cash and cash equivalents	155,127,000	114,454,000	155,127,000
Restricted cash	1,299,000	1,103,000	1,299,000
Total cash, cash equivalents and restricted cash, end of the period	156,426,000	115,557,000	156,426,000
Supplemental disclosure of non-cash investing and financing activities:
Lease liabilities arising from obtaining right-of-use assets		4,506,000	0
Capitalized internal-use software development costs accrued and not yet paid		117,000	0
Vesting of early exercised stock options and restricted stock awards	$ 27,000	$ 107,000	$ 225,000